GE Healthcare has landed three new collaborative partners in its quest to advance care for cancer patients. SOPHiA GENETICS, Optellum, and The University of Cambridge will each bring their unique offerings to the fore in the interest of making precision health more widely available and improving overall outcomes for individuals with cancer.
SOPHiA GENETICS will work with GE on myriad initiatives and projects in the areas of radiogenomic analysis and digital oncology. They plan to create an infrastructure capable of integrating data between their platforms, SOPHiA DDM and GE's Edison. The companies will also tackle co-marketing and pilot-site recruitment for oncology and radiogenomics endeavors.
The University of Cambridge as well as Cambridge University Hospitals are collaborating with GE to develop an application aimed at enhancing cancer care. Cambridge, for its part, will chime in with the clinical expertise and data needed to buoy GE's ambitious scheme for an AI-enhanced application that incorporates cancer patient data from various sources into a consolidated interface. The offering builds on research supported by The Mark Foundation for Cancer Research and Cancer Research UK in addressing the problem of disconnected patient information.
Optellum, a U.K.-based company that has made its name through top-notch AI-decision support for lung cancer diagnosis and treatment, is joining with GE to give providers better diagnostic clarity for that cancer. The only FDA-approved AI-assisted diagnosis software for early-stage lung cancer, Optellum's Virtual Nodule Clinic grades the likelihood of malignancy in a lung nodule, helping determine biopsy necessity and speed diagnosis time.
